Abstract
We investigated whether the efficacy of fenretinide (HPR) against ovarian tumours may be limited by induction of resistance. The human ovarian carcinoma cell line A2780, which is sensitive to a pharmacologically achievable HPR concentration (IC50=1 μM), became 10-fold more resistant after exposure to increasing HPR concentrations. The cells (A2780/HPR) did not show cross-resistance to the synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) and were not sensitive, similarly to the parent line, to all-trans-retinoic acid, 13-cis-retinoic acid or N-(4-methoxyphenyl)retinamide. A2780/HPR cells showed, compared to parental cells, a 3-fold reduction in colony-forming ability in agar. The development of HPR resistance was associated with a marked increase in retinoic acid receptor β (RARβ) mRNA and protein levels, which decreased, together with drug resistance, after drug removal. The expression of cell surface molecules associated with tumour progression including HER-2, laminin receptor and β1 integrin was markedly reduced. The increase in the levels of reactive oxygen species is not involved in HPR-resistance because it was similar in parental and resistant cells. Conversely differences in pharmacokinetics may account for resistance because, in A2780/HPR cells, intracellular peak drug levels were 2 times lower than in A2780 cells and an as yet unidentified polar metabolite was present. These data suggest that acquired resistance to HPR is associated with changes in marker expression, suggestive of a more differentiated status and may be explained, at least in part, by reduced drug accumulation and increased metabolism. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Sopert JT, Dodge R, Clarke-Pearson DL, Marks P, Mckenzie S, Yin S and Bast RC, Jr (1990) Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–4091
Braakhuis BJM, Klaassen I, Van Der Leede BM, Cloos J, Brakenhoff RH, Copper MP, Teerlink T, Hendriks HFJ, Van Der Saag PT and Snow GB (1997) Retinoid metabolism and all-trans retinoic acid-induced growth inhibition in head and neck squamous cell carcinoma cell lines. Br J Cancer 76: 189–197
Clifford JL, Menter DG, Wang M, Lotan R and Lippman SM (1999) Retinoid receptor-dependent and - independent effects of N-(4-hydroxyphenyl) retinamide in F9 embryonal carcinoma cells. Cancer Res 59: 14–18
De Palo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, Fosser V, Del Vecchio M, Campa T, Costa A and Marubini E (1995) Can fenretinide protect women against ovarian cancer?. J Natl Cancer Inst 87: 146–147
Dolo V, Ginestra A, Violini S, Miotti S, Festuccia C, Miceli D, Migliavacca M, Rinaudo C, Romano FM, Brisdelli F, Canevari S, Pavan A and Vittorelli ML (1997) Ultrastructural and phenotypic characterization of CABA I, a new human ovarian carcinoma cell line. Oncol Res 9: 129–138
Fanjul A, Delia D, Pierotti MA, Rideout D, Qiu J and Pfahl M (1996) 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271: 22441–22446
Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, Moglia D, De Palo G, Costa A and Veronesi U (1993) Five year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11: 2036–2042
Formelli F, Barua AB and Olson JA (1996) Bioactivities of N-(4-hydroxyphenyl)retinamide and retinoyl β-glucuronide. FASEB J 10: 1014–1024
Houle B, Rochette-Egly C and Bradley WEC (1993) Tumour-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc Natl Acad Sci 90: 985–989
Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK and Lotan R (1997) Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 89: 1191–1198
Pellegrini R, Mariotti A, Tagliabue E, Bressan R, Bunone G, Coradini D, Della Valle G, Formelli F, Cleris L, Radice P, Pierotti MA, Colnaghi MI and Menard S (1995) Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl)retinamide. Cell Growth and Diff 6: 863–869
Pergolizzi R, Appierto V, Crosti M, Cavadini E, Cleris L, Guffanti A and Formelli F (1999) Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int J Cancer 81: 829–834
Ponzanelli I, Gianni M, Giavazzi R, Garofalo, Nicoletti I, Reichert U, Erba E, Rambaldi A, Terao M and Garattini E (2000) Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. Blood 95: 2672–2682
Rozzo C, Chiesa V, Caridi G, Pagnan G and Ponzoni M (1997) Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer 70: 688–698
Supino R, Crosti M, Clerici M, Walters A, Cleris L, Zunino F and Formelli F (1996) Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 65: 491–497
U.K. Coordinating Committee on Cancer Research (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58: 109–113
Van den Brule FA, Castronovo V, Menard S, Giavazzi R, Marzola M, Belotti D and Taraboletti G (1996) Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. Eur J Cancer 32A: 1598–1602
Van der Leede B-JM, Van den Brink CE, Pijnappel WWM, Sonneveld E, Van der Saag PT and Van der Burg B (1997) Autoinduction of retinoic acid metabolism to polar derivatives with decreased biological activity in retinoic acid-sensitive, but not in retinoic acid-resistant human breast cancer cells. J Biol Chem 272: 17921–17928
Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Rosselli del Turco M, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R and Sporn MB for the Fenretinide Trial Investigators (1999) A randomized trial of fenretinide, a vitamin A analog, to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Appierto, V., Cavadini, E., Pergolizzi, R. et al. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer 84, 1528–1534 (2001). https://doi.org/10.1054/bjoc.2001.1826
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1826
Keywords
This article is cited by
-
Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content
Glycoconjugate Journal (2012)
-
Impact of 4HPR on the expression of E-Cad in human bladder transitional epithelial cancer cells T24
Journal of Huazhong University of Science and Technology [Medical Sciences] (2012)
-
Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells
BMC Cancer (2011)
-
The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3β pathway and β-catenin stability
Molecular Cancer (2010)
-
Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide
Cancer Chemotherapy and Pharmacology (2008)